NCT02880345 is a Phase 1 clinical trial of PEMBROLIZUMAB in Urothelial Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

Who is sponsoring NCT02880345?

NCT02880345 is sponsored by Abramson Cancer Center at Penn Medicine.

What drugs are being tested in NCT02880345?

Interventions in NCT02880345: PEMBROLIZUMAB, hypofractionated radiation.

What condition does NCT02880345 study?

NCT02880345 studies Urothelial Cancer.

Is NCT02880345 still recruiting?

NCT02880345 is currently withdrawn. Last updated 22 April 2019.

Last reviewed 2019-04-22 · How we verify

NCT02880345

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RADVAX™: A Pilot Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

Withdrawn Phase 1 Last updated 22 April 2019

What this trial tests

Phase 1 trial testing PEMBROLIZUMAB in Urothelial Cancer. Withdrawn.

Timeline

1 August 2016

Primary endpoint
1 August 2017

1 December 2018

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Start date	1 August 2016
Primary completion	1 August 2017
Estimated completion	1 December 2018
Sites	1 location across United States

Drugs / interventions tested

PEMBROLIZUMAB (pembrolizumab) — full drug profile →
hypofractionated radiation

Conditions studied

Urothelial Cancer — all drugs for Urothelial Cancer →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, any sex, with Urothelial Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Adverse Events
Time frame: 2 years

Sponsor's own description

This is a pilot study of a fixed dose of Pembrolizumab in combination with two different regimens of hypofractionated radiation. It is designed to demonstrate the activity and safety of the combination treatment in advanced urothelial cancer patients with prior exposure to PD-1 inhibitors.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.
Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, et al · · 2018 · cited 52× · PMID 29892196 · DOI 10.2147/tcrm.s158753
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
Johnson CB, Win SY. · · 2018 · cited 26× · PMID 29632719 · DOI 10.1080/2162402x.2017.1408744
Radiotherapy and immune checkpoint blockades: a snapshot in 2016.
Koo T, Kim IA. · · 2016 · cited 24× · PMID 28030901 · DOI 10.3857/roj.2016.02033
Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
Zichi C, Tucci M, Leone G, Buttigliero C, et al · · 2017 · cited 10× · PMID 28680882 · DOI 10.1155/2017/5618174

Verify or expand the search:

Other recruiting trials for Urothelial Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
NCT07106762 — Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease · Phase 2, PHASE3 · recruiting
NCT07129993 — Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Partic · Phase 2, PHASE3 · recruiting
NCT06011954 — A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection · recruiting

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02880345 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 22 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02880345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing